American Journal of Medical Genetics · 2000 · 34 citations · 24 references
Life SciencesGeneticsNeuroscienceHuman GeneticsMolecular NeuroscienceNeurodegenerationAmyloid FormationBiomarkers Of NeurodegenerationDown SyndromeNeurodegenerative DiseasesNeurodegenerative DisordersNeurodevelopmental DisordersAmyloid Beta AggregationAmyloid Beta PeptidesAmyloid Beta PlaquesMental Status Examination Affect
In Down syndrome (DS) brain an early, selective accumulation of amyloid beta (Abeta) peptides ending at residue 42 (Abeta42) occurs. Whether this event depends on an altered processing of amyloid beta precursor protein (APP) or on defective clearance is uncertain. To investigate this issue, we measured Abeta species 40 and 42 in plasma from 61 patients with DS, 77 age-matched normal controls, and 55 mentally retarded subjects without chromosomal abnormalities. The Abeta 40 and 42 plasma levels were then correlated with apolipoprotein E (apoE) genotypes in all groups of cases, and with I. Q. and Mini Mental Status Examination values in DS subjects. Both Abeta species were significantly elevated in DS compared to control groups, and the extent of their increase reflects that expected from APP gene overexpression. Plasma levels of Abeta 40 and 42 did not correlate with apoE genotypes in DS and control cases, and with the extent of mental retardation in DS subjects. The results indicate that accumulation and clearance of plasma and cerebral Abeta are regulated by different and independent factors.
24
Donalyn Scheuner, Christopher B. Eckman, M. Jensen et al. · Nature Medicine · 1996 · 2.6K citations
Amyloid β-peptide is produced by cultured cells during normal metabolism
Christian Haass, Michael G. Schlossmacher, Albert Y. Hung et al. · Nature · 1992 · 1.9K citations
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Peter Seubert, Carmen Vigo‐Pelfrey, Fred Esch et al. · Nature · 1992 · 1.7K citations